Publicaciones en colaboración con investigadores/as de Rush University Medical Center (14)

2023

  1. An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)

    Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828

  2. Editorial: Nutrition and neurodegenerative diseases: insights and perspectives on prevention strategies

    Frontiers in Nutrition

  3. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma: Final Data from the Phase 2 ELOQUENT-3 Trial

    HemaSphere, Vol. 7, Núm. 3, pp. E843

2022

  1. Melphalan flufenamide for relapsed/refractory multiple myeloma

    Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423

  2. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 639-648

2021

  1. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767

2020

  1. Imaging-AMARETTO: An imaging genomics software tool to interrogate multiomics networks for relevance to radiography and histopathology imaging biomarkers of clinical outcomes

    JCO Clinical Cancer Informatics, Vol. 4, pp. 421-435

  2. Melflufen for relapsed and refractory multiple myeloma

    Expert Opinion on Investigational Drugs, Vol. 29, Núm. 10, pp. 1069-1078

2019

  1. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial

    JAMA Psychiatry, Vol. 76, Núm. 9, pp. 893-903

2015

  1. Convergent genetic and expression data implicate immunity in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 11, Núm. 6, pp. 658-671

2014

  1. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease

    PLoS ONE, Vol. 9, Núm. 6

2013

  1. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

    Nature Genetics, Vol. 45, Núm. 12, pp. 1452-1458

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

2004

  1. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

    Biology of Blood and Marrow Transplantation, Vol. 10, Núm. 10, pp. 698-708